Tonix Pharmaceuticals Publishes Peer-Reviewed Publication In MSphere Journal Highlighting Tolerability Of Its Single-Dose Mpox And Smallpox Vaccine Candidate TNX-801, In Immune-Compromised Animals
Tonix Pharmaceuticals Publishes Peer-Reviewed Publication In MSphere Journal Highlighting Tolerability Of Its Single-Dose Mpox And Smallpox Vaccine Candidate TNX-801, In Immune-Compromised Animals
The World Health Organization (WHO) declared the spread of new Clade Ib Mpox a public health emergency of international concern (PHEIC): Second Mpox-related WHO PHEIC declaration in two years
世界卫生组织（WHO）将新克莱德Ib Mpox的传播宣布为国际关注的公共卫生紧急事件（PHEIC）：这是两年来第二次与Mpox相关的WHO PHEIC声明
Clade Ib Mpox cases detected in 16 African countries and outside of Africa, in Sweden, Thailand, Singapore, India, Germany and England
在16个非洲国家以及瑞典、泰国、新加坡、印度、德国和英国发现了克莱德Ib Mpox病例
Single-dose mpox vaccines with durable protection may be required to address global health emergency
可能需要单剂量的mpox疫苗以提供持久的保护，来应对全球健康紧急事件
TNX-801 was shown to be more than 10- to 1,000-fold more attenuated (or less virulent) compared to the older vaccinia smallpox vaccines: Tolerability of TNX‐801 vaccination in immune-compromised animal models supports clinical development
与旧的水痘疫苗相比，TNX-801的减毒超过了10到1,000倍（或致病性更低）：TNX-801在免疫受损动物模型中的耐受性支持了其临床开发
